Back to Search
Start Over
Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.
- Source :
-
British Journal of Haematology . Dec2015, Vol. 171 Issue 5, p710-719. 10p. 1 Diagram, 5 Charts, 1 Graph. - Publication Year :
- 2015
-
Abstract
- In the multicentre prospective randomized HD2002 trial, rituximab maintenance therapy (375 mg/m² every 3 months for 2 years) versus observation was evaluated for CD20+ B-cell lymphoma. Out of 321 patients [161 randomized to the treatment group (TG), 160 to the observation group (OG)], 295 data sets were evaluable for statistical analysis. Estimated 5-year relapse-free survival (RFS) was 81% in the TG and 70% in the OG (logrank test, P = 0.047). In the diffuse large B-cell lymphoma (DLBCL) subgroup (n = 152), 5-year RFS was excellent, at 87% in the TG and 84% in the OG (logrank test, P = 0.35). Of note, only in male patients of the DLBCL subgroup was RFS significantly superior in the TG in comparison to the OG (5-year RFS: 88% vs. 74%; logrank test, P = 0.05). Cox regression analysis showed a significant interaction between treatment and gender regarding overall survival (OS) (P = 0.006) and RFS (P = 0.02), with a lower hazard in females than males in the OG [OS: hazard ratio (HR) (female:male) = 0.11; 95% confidence interval (CI) = 0.00-1.03; RFS: HR (female:male) = 0.27; 95% CI = 0.05-0.97], and no significant differences between males and females in the TG. We conclude that Rituximab maintenance therapy improves survival in male patients with DLBCL. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 171
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 111145766
- Full Text :
- https://doi.org/10.1111/bjh.13652